ACTRN12618000285257已完成3 期
A double-blind, randomised, placebo-controlled study to evaluate the effect of orally-dosed LipiSperse curcumin and/or palmitoylethanolamide (PEA) on exercise recovery in healthy males.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 35 Years（—）
- 性别
- Male
入选标准
- •Recreationally trained males (150 minutes of exercise per week and 6 months of resistance training experience in the last year) between 18 and 35 years old
- •Normal dietary habits (no medically prescribed diet, no slimming diet, no vegan or macrobiotic diet)
- •Otherwise healthy, BMI 18.5-35
- •Able to provide informed consent
排除标准
- •Unstable or serious illness (e.g. kidney, liver, GIT, heart conditions, diabetes)
- •Use of long-term medication
- •Malignancy or treatment for malignancy within the previous 2 years
- •Receiving/ prescribed coumadin (Warfarin), heparin, daltaparin, enoxaparin
- •or other anticoagulation therapy
- •Active smokers
- •Chronic past and/or current alcohol use (>14 alcoholic drinks week)
- •Allergic to any of the ingredients in active or placebo formula
- •People with serious mood disorders (such as depression and bipolar disorder)
- •will be excluded. The Hamilton Rating Scale for Depression could be used as a screening form to ensure that those with undiagnosed depression are not enrolled into the study.
- •Those suffering from insomnia or have night-shift employment and unable to have a normal night’s sleep
- •People suffering any neurological disorders such as MS
- •Any condition which in the opinion of the investigator makes the participant
- •unsuitable for inclusion. This include existing and recent musculoskeletal
- •Participants who have participated in any other clinical trial during the past 3
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyltransferase activity and motor response in parkinson´s disease patients treated with levodopa/dopa-decarboxylaseinhibitorParkinson’s DiseaseMedDRA version: 17.1Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 100000004852EUCTR2009-012897-12-ROBIAL-Portela & Ca, SA32
已完成
不适用
A double-blind, randomised, placebo-controlled study to evaluate the effect of an orally-dosed herbal formulation containing Testofen, on sexual function, performance, and serum testosterone levels in healthy males.Sexual performanceSexual functionAlternative and Complementary Medicine - Herbal remediesMetabolic and Endocrine - Other metabolic disordersACTRN12611000830998AZPA International60
进行中（未招募）
1 期
Clinical trial to assess the effect of SNF472 on progression of build up of calcium in coronary blood vessels in patients with kidney disease.EUCTR2016-002834-59-ESaboratoris Sanifit450
进行中（未招募）
1 期
Clinical trial to assess the effect of SNF472 on progression of build up of calcium in coronary blood vessels in patients with kidney disease.Cardiovascular calcification in blood vessels in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).MedDRA version: 20.1 Level: LLT Classification code 10014646 Term: End stage renal disease (ESRD) System Organ Class: 100000004857MedDRA version: 20.0 Level: PT Classification code 10051753 Term: Vascular calcification System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0 Level: PT Classification code 10018875 Term: Haemodialysis System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-002834-59-GBSanifit Therapeutics S.A.270
已完成
2 期
A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostateBenign Prostatic HypertrophyAlternative and Complementary Medicine - Herbal remediesRenal and Urogenital - Other renal and urogenital disordersACTRN12610000168055Totally Natural Products68